The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010,
and the second edition was published in 2015 by the Japanese Society of Gastroenterology …

Nonalcoholic steatohepatitis (NASH) has become a focus for drug development owing to its
increasing prevalence and health care burden. The global prevalence of NASH is estimated …

Background Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic
response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the impact …

Background We recently reported the real-world changes in the etiologies of liver cirrhosis
(LC) based on nationwide survey data and assessed the etiologies of LC with hepatocellular …

It has been estimated by the World Health Organization (WHO) that over 71 million people
were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly …

Background Real-world data on the efficacy and safety of sofosbuvir plus velpatasvir
(SOF/VEL) treatment for patients with hepatitis C virus (HCV)-related decompensated …

Background The effects of direct-acting antivirals (DAAs) on survival and recurrence rates
after curative hepatocellular carcinoma (HCC) treatment in patients with hepatitis C virus …

The Drafting Committee for Hepatitis Management Guidelines established by the Japan
Society of Hepatology (JSH) drafted the first version of the clinical practice guidelines for the …

In recent years, the development of diagnostics using artificial intelligence (AI) has been
remarkable. AI algorithms can go beyond human reasoning and build diagnostic models …

The real‐world virological efficacy and safety of interferon‐free direct‐acting antiviral (DAA)
therapy with sofosbuvir (SOF) and velpatasvir (VEL) were assessed in hepatitis C virus …